Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer
2022-004122-22Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of monalizumab and volrustomig in Non-hematologic malignancy, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Safety profile during safety lead-in. Started Jan 2023; status: active.
02
Drugs
monalizumabvolrustomig
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2022-004122-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004122-22.